Benchmark for Setting ACTH Cell Dosage in Clinical Regenerative Medicine for Post-Operative Hypopituitarism

Background/Objectives: Our objective is to develop hormone-producing pituitary cells that can function in the same manner as the human body and provide more effective treatments than current hormone replacement therapy. We have already established a technique for generating hypothalamic–pituitary or...

Full description

Saved in:
Bibliographic Details
Main Authors: Tatsuma Kondo, Hidetaka Suga, Kazuhito Takeuchi, Yutaro Fuse, Yoshiki Sato, Toshiaki Hirose, Harada Hideyuki, Yuichi Nagata, Ryuta Saito
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Diseases
Subjects:
Online Access:https://www.mdpi.com/2079-9721/13/4/112
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849713627070726144
author Tatsuma Kondo
Hidetaka Suga
Kazuhito Takeuchi
Yutaro Fuse
Yoshiki Sato
Toshiaki Hirose
Harada Hideyuki
Yuichi Nagata
Ryuta Saito
author_facet Tatsuma Kondo
Hidetaka Suga
Kazuhito Takeuchi
Yutaro Fuse
Yoshiki Sato
Toshiaki Hirose
Harada Hideyuki
Yuichi Nagata
Ryuta Saito
author_sort Tatsuma Kondo
collection DOAJ
description Background/Objectives: Our objective is to develop hormone-producing pituitary cells that can function in the same manner as the human body and provide more effective treatments than current hormone replacement therapy. We have already established a technique for generating hypothalamic–pituitary organoids using feeder-free human pluripotent stem cells (hPSCs) and demonstrated their effectiveness in vivo through transplantation into hypopituitary mouse models. To prospectively determine the upper limit of transplanting adenohypophyseal cells into humans, we investigated the human maximum secretion capacity of adrenocorticotropic hormone (ACTH) and growth hormone (GH). Methods: We analyzed data from 28 patients with pituitary adenomas, among whom 16 evinced no abnormality of ACTH secretion and 12 showed no GH secretion on corticotropin-releasing hormone (CRH) and growth hormone-releasing hormone-2 (GHRP-2) stimulation testing. Results: The average ACTH peak value after CRH stimulation tests was 97.2 pg/mL, and the average GH peak value after GHRP-2 stimulation tests was 25.1 ng/mL. Conclusions: These data will likely serve as benchmarks of ACTH and GH secretion when transplanting cultured cells into humans.
format Article
id doaj-art-c697c0183f98475a8b5795ce3d682b6d
institution DOAJ
issn 2079-9721
language English
publishDate 2025-04-01
publisher MDPI AG
record_format Article
series Diseases
spelling doaj-art-c697c0183f98475a8b5795ce3d682b6d2025-08-20T03:13:54ZengMDPI AGDiseases2079-97212025-04-0113411210.3390/diseases13040112Benchmark for Setting ACTH Cell Dosage in Clinical Regenerative Medicine for Post-Operative HypopituitarismTatsuma Kondo0Hidetaka Suga1Kazuhito Takeuchi2Yutaro Fuse3Yoshiki Sato4Toshiaki Hirose5Harada Hideyuki6Yuichi Nagata7Ryuta Saito8Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 468-0066, JapanDepartment of Endocrinology and Diabetes, Graduate School of Medicine, Nagoya University, Nagoya 468-0066, JapanDepartment of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 468-0066, JapanDepartment of Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8722, JapanDepartment of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 468-0066, JapanDepartment of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 468-0066, JapanDepartment of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 468-0066, JapanDepartment of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 468-0066, JapanDepartment of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 468-0066, JapanBackground/Objectives: Our objective is to develop hormone-producing pituitary cells that can function in the same manner as the human body and provide more effective treatments than current hormone replacement therapy. We have already established a technique for generating hypothalamic–pituitary organoids using feeder-free human pluripotent stem cells (hPSCs) and demonstrated their effectiveness in vivo through transplantation into hypopituitary mouse models. To prospectively determine the upper limit of transplanting adenohypophyseal cells into humans, we investigated the human maximum secretion capacity of adrenocorticotropic hormone (ACTH) and growth hormone (GH). Methods: We analyzed data from 28 patients with pituitary adenomas, among whom 16 evinced no abnormality of ACTH secretion and 12 showed no GH secretion on corticotropin-releasing hormone (CRH) and growth hormone-releasing hormone-2 (GHRP-2) stimulation testing. Results: The average ACTH peak value after CRH stimulation tests was 97.2 pg/mL, and the average GH peak value after GHRP-2 stimulation tests was 25.1 ng/mL. Conclusions: These data will likely serve as benchmarks of ACTH and GH secretion when transplanting cultured cells into humans.https://www.mdpi.com/2079-9721/13/4/112pituitary regenerative medicinepituitary glandadrenocorticotropic hormone
spellingShingle Tatsuma Kondo
Hidetaka Suga
Kazuhito Takeuchi
Yutaro Fuse
Yoshiki Sato
Toshiaki Hirose
Harada Hideyuki
Yuichi Nagata
Ryuta Saito
Benchmark for Setting ACTH Cell Dosage in Clinical Regenerative Medicine for Post-Operative Hypopituitarism
Diseases
pituitary regenerative medicine
pituitary gland
adrenocorticotropic hormone
title Benchmark for Setting ACTH Cell Dosage in Clinical Regenerative Medicine for Post-Operative Hypopituitarism
title_full Benchmark for Setting ACTH Cell Dosage in Clinical Regenerative Medicine for Post-Operative Hypopituitarism
title_fullStr Benchmark for Setting ACTH Cell Dosage in Clinical Regenerative Medicine for Post-Operative Hypopituitarism
title_full_unstemmed Benchmark for Setting ACTH Cell Dosage in Clinical Regenerative Medicine for Post-Operative Hypopituitarism
title_short Benchmark for Setting ACTH Cell Dosage in Clinical Regenerative Medicine for Post-Operative Hypopituitarism
title_sort benchmark for setting acth cell dosage in clinical regenerative medicine for post operative hypopituitarism
topic pituitary regenerative medicine
pituitary gland
adrenocorticotropic hormone
url https://www.mdpi.com/2079-9721/13/4/112
work_keys_str_mv AT tatsumakondo benchmarkforsettingacthcelldosageinclinicalregenerativemedicineforpostoperativehypopituitarism
AT hidetakasuga benchmarkforsettingacthcelldosageinclinicalregenerativemedicineforpostoperativehypopituitarism
AT kazuhitotakeuchi benchmarkforsettingacthcelldosageinclinicalregenerativemedicineforpostoperativehypopituitarism
AT yutarofuse benchmarkforsettingacthcelldosageinclinicalregenerativemedicineforpostoperativehypopituitarism
AT yoshikisato benchmarkforsettingacthcelldosageinclinicalregenerativemedicineforpostoperativehypopituitarism
AT toshiakihirose benchmarkforsettingacthcelldosageinclinicalregenerativemedicineforpostoperativehypopituitarism
AT haradahideyuki benchmarkforsettingacthcelldosageinclinicalregenerativemedicineforpostoperativehypopituitarism
AT yuichinagata benchmarkforsettingacthcelldosageinclinicalregenerativemedicineforpostoperativehypopituitarism
AT ryutasaito benchmarkforsettingacthcelldosageinclinicalregenerativemedicineforpostoperativehypopituitarism